← 返回

淋巴细胞归巢与再循环及肿瘤三级淋巴结构形成:对成功肿瘤免疫治疗的预测

英文原题:Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy.

查看英文原题

Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy.

PubMed 2024/07/15(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

淋巴细胞持续归巢至淋巴结构的能力,对癌症免疫监视和免疫治疗具有重要意义。现已认识到,肿瘤微环境(TME)中淋巴细胞归巢和再循环属于适应性过程,受特定细胞因子及黏附分子信号级联调控。淋巴细胞浸润和再循环受限,已成为导致CAR-T 细胞疗法和免疫检查点阻断(ICB)等癌症免疫治疗应答不佳的关键机制。揭示淋巴细胞浸润肿瘤及循环的动态过程,对于改进免疫疗法至关重要。本综述讨论目前对淋巴细胞归巢和跨内皮迁移相关黏附分子及迁移分子的认识,并总结TME内限制淋巴细胞浸润的潜在机制。在此基础上,文章概述肿瘤内三级淋巴结构(TLS)形成的决定因素,并高度关注TLS作为恶性肿瘤预后指标和治疗靶点的潜在价值。

展开英文摘要原文

The capacity of lymphocytes continuously home to lymphoid structures is remarkable for cancer immunosurveillance and immunotherapy. Lymphocyte homing and recirculation within the tumor microenvironment (TME) are now understood to be adaptive processes that are regulated by specialized cytokines and adhesion molecule signaling cascades. Restricted lymphocyte infiltration and recirculation have emerged as key mechanisms contributing to poor responses in cancer immunotherapies like chimeric antigen receptor (CAR)-T cell therapy and immune checkpoint blockades (ICBs).

Uncovering the kinetics of lymphocytes in tumor infiltration and circulation is crucial for improving immunotherapies. In this review, we discuss the current insights into the adhesive and migrative molecules involved in lymphocyte homing and transmigration.

The potential mechanisms within the TME that restrain lymphocyte infiltration are also summarized. Advanced on these, we outline the determinates for tertiary lymphoid structures (TLSs) formation within tumors, placing high expectations on the prognostic values of TLSs as therapeutic targets in malignancies.

论文信息

作者
Tian W、Wei W、Qin G、Bao X、Tong X、Zhou M、Xue Y、Zhang Y
单位
Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 39076974 · DOI 10.3389/fimmu.2024.1403578